In this episode of The DrBicuspid.com Podcast, Kevin Henry speaks with Drs. Hong Cheol Yoon and Michael Miyasaki about the innovative biofluorescence technology developed by AIOBIO. They discuss the shift from reactive to preventive dentistry, the importance of building trust with patients through visual tools, and the commitment required for success in the dental field. The conversation also touches on the pair's goals for 2026, focusing on expanding the use of biofluorescence technology in the U.S.
Regarding the help provided by Cellerant Consulting in establishing AIOBIO in the U.S., Dr. Yoon said, "It has always been challenging for companies like ours to access the core groups of United States dentistry. Cellerant played a meaningful role in opening that door and connecting us with the right leaders. That impact has been one of the most valuable outcomes for us."
Podcast takeaways
- AIOBIO focuses on preventive dentistry through biofluorescence technology.
- The shift from reactive to preventive care is crucial in modern dentistry.
- Patient education is key to successful treatment acceptance.
- Trust between the dentist and patient enhances care outcomes.
- Continuous feedback from real-world use drives innovation at AIOBIO.
- Leadership in dentistry requires commitment and adaptability.
- The integration of technology can improve patient outcomes.
- Biofluorescence technology helps visualize oral health issues.
- AIOBIO's future goals include expanding the use of innovative technologies in the U.S.
- Dentists must balance business needs with patient care.
